Genmab — December 2019

[Solsen]

Dont you think we get an update on the pipeline in generel.

[Sukkeralf]

We will: Genmab speakers will also discuss the company’s pipeline, progress and key goals for 2020

[Sukkeralf]

for sure hexaCD38 will be mentioned

[Sukkeralf]

its a clinical candidate next year

[Solsen]

I think we have to look at DR5 as a lottery ticket.

[Sukkeralf]

Yes but hopefully its the target thats still a problem even with a more potent compound - and not the technology

[E_L]

not sure if this video was posted already - ASH 2019 | Early prevention of myeloma: dara for high-risk MGUS and low-risk SMM - https://www.vjhemonc.com/video/quccqyli-m0-early-prevention-of-myeloma-dara-for-high-risk-mgus-and-low-risk-smm/

[E_L]

ok, as I was hoping, on CHMP agenda this week Dara SC and for the 2nd time (daratumumab) in combination with bortezomib, thalidomide and dexamethasone https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-9-12-december-2019-meeting_en.pdf

[GeorgeBest]

Bluebird startede 5% op, men er nu minus 1%, så der er da ikke meget CAR-T eufori i aktiekurserne....

[GeorgeBest]

TAK-079: Takeda får heller ikke noget boost....

[nohope]

U-TAK - er verdens løn...

[E_L]

the HexaBody-CD38 poster, courtesy Kempen https://twitter.com/KempenLS/status/1204059369480036354

[mobbyduck1]

nice one EL

[Helge_LarsenPI-redaktør]

Sorry..Jeg kan simpelthen ikke læse posteren her på mobilen. Hvad er headlines?

[Bulder]

enhanzed cdc compared to dara

[Bulder]

did not induce lysis of normal cells but did lisys on NK cells

[Bulder]

ellers er det vist det samme som der står i abstr.

[Mcjean]

svært at læse graferne men konklusionen er vel ikke meget ny, gode i mus og skal undersøges nærmere

[Bulder]

desværre angriber den også NK-celler, men det kunne man vel forvente, når det var en af daras svagheder.

[E_L]

a bit less as in Dara, if i see it correct in those little charts